Neuromyelitis Optica Spectrum Disorder (NMOSD) Market by Application, Type and Geography - Forecast and Analysis 2023-2027

Published: Oct 2023 Pages: 138 SKU: IRTNTR75785

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast 2023-2027

The global neuromyelitis optica spectrum disorder (NMOSD) market size is estimated to grow/decline by USD 173.48 million at a CAGR of 6.16% between 2022 and 2027. 

The growing geriatric population is driving the market growth. NMOSD is an autoimmune demyelinating disease that involves demyelination of mostly the optic nerves and spinal cord and is primarily observed in the elderly population. According to the National Institutes of Health (NIH), it is more prevalent in people above 50 years of age. Some optical disorders that have a higher risk of development with age include cataracts, glaucoma, and dry eye syndrome.

What will be the size of the Neuromyelitis Optica Spectrum Disorder Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by Application, Type, and Geography Analysis

Application Analysis 

Hospitals segment

The market share growth by the hospitals segment will be significant during the forecast period, as indicated by market forecasting. Multi-specialty hospitals and private hospital groups that operate on government or private sponsorships work in close collaboration with medicine suppliers and government bodies to purchase medicines and consumables in bulk, reflecting market growth and trends.

The presence of a well-equipped medical infrastructure helps in the diagnosis and monitoring of chronic diseases, aligning with market analysis and report. The treatment and monitoring of chronic diseases are generally conducted in an outpatient facility by skilled staff. Technologically advanced methods such as magnetic resonance imaging (MRI) are used primarily in the diagnosing of NSMOD, showcasing market forecast.

Get a glance at the contribution of various segments View a PDF Sample

The hospitals segment was valued at USD 196.59 million in 2017. There are several mid-sized hospitals that work with local industries, have fewer hospital beds (200-300), and have a decentralized administration compared to multi-specialty hospitals, as observed in market trends and analysis. Additionally, they have skilled professionals and continuous treatment for symptomatic and curative treatment, contributing to market growth analysis. These factors will also propel the growth of the global neuromyelitis optica spectrum disorder market during the forecast period, aligning with market research and growth and market growth and forecasting.

Market Analyst Overview

The Neuromyelitis Optica Spectrum Disorder (NMOSD) Market occupies a unique position within the rare disease market and neurological disorder market, offering specialized therapeutic options for patients. As research into disease pathophysiology advances, novel treatment options emerge, expanding disease management strategies and improving patient care. Clinical trials focusing on immunotherapy contribute to the evolution of the neurology market, driving medical innovation and enhancing symptom management techniques.

Increased disease awareness among healthcare professionals and patients fosters collaboration in research and development efforts, shaping the landscape of the healthcare market and pharmaceutical industry. With a focus on drug development and specialized medications, the NMOSD Market addresses the unique needs of patients in the specialty medicine market, providing hope for improved outcomes and enhanced quality of life.

Type Analysis

With aquaporin-4 antibodies segment 

The growth of the with Aquaporin-4 (AQP4) antibodies segment, an antigen found in more than 75% of NSMOD patients. Patients with AQP4 antigens might have attacks of the AQP4 protein in the brain, spinal cord, and optic nerve. One of the drugs used to prevent relapsing NSMOD in these patients is Ecluzimab, a terminal complement inhibitor. Hence, drugs and treatment methods for the population with AQP4 antibodies are expected to result in the growth of the global neuromyelitis Optica spectrum disorder during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 37% to the growth of the global during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the during the forecast period. Within North America, the largest region in the global neuromyelitis Optica spectrum disorder, the US and Canada are the largest markets due to the presence of pharmaceutical giants in the region, and a higher prevalence rate of neuromyelitis Optica spectrum disorder. This has witnessed growth due to the growing geriatric population, increased screen time, and awareness of the condition and its treatment.

Additionally, numerous pharmaceutical companies are involved in the manufacture and sales of neuromyelitis optica spectrum disorder drugs in North America including Genetech and Viela bio. These factors are likely to boost the growth of the during the forecast period.

Buy Now Full Report and Discover More

Key Market Players 

industries are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence. The report also includes detailed analyses of the competitive landscape of the market and information about 9 key industries, including:

AstraZeneca - The company offers Ultomiris for the treatment of neuromyelitis optica spectrum disorder.

  • Biogen Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • HBM Holdings Ltd.
  • Horizon Therapeutics Plc
  • TG Therapeutics Inc.
  • Mitsubishi Chemical Group Corp.
  • Opexa Therapeutics Inc.

Qualitative and quantitative analysis of industries has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key players. Data is qualitatively analyzed to categorize industries as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize industries as dominant, leading, strong, tentative, and weak.

Key Drivers, Trends, Challenges, and Customer Landscape

Key Drivers

The growing geriatric population is driving the growth. NMOSD is characterized by demyelination of the optic nerves and spinal cord and is primarily found in the elderly population. Asia is a highly lucrative region for disorders like NSMOD due to its growing geriatric population. However, North America and Europe hold the major shares in the owing to higher investments in the healthcare sector. Some age-related eye disorders include age-related macular degeneration (AMD), diabetic eye disease, and low vision.

Additionally, the likelihood of developing dry eye syndrome increases with age due to reduced tear production. Hence, the above factors are likely to increase the demand for neuromyelitis Optica spectrum disorder drugs which will result in growth during the forecast period.

Key Trends

Advances in the treatment of NMOSD is a key trend. Several prescriptions for the treatment of NMOSD are available with a varying range of drugs, mechanisms, and endpoints. Generally, they serve as the first line of therapy along with anti-coagulant medications, such as corticosteroids (glucocorticoid), azathioprinol, or RITUXIMAB for NMOSD patients. For and as the second line of treatment for NMOSD patients they are used in combination with immunosuppressants like Methotrexate and Mitoxantrone.

Additionally, there is research into refining existing strategies for the treatment of long-term disability and mortality associated with NMOSD with stem cell therapy being part of it. It gives various advantages including regulation of immune response and promoting local tissue repair and regeneration. This suggests there is a therapeutic potential of hUC-MSC to treat autoimmune disorders like NSMOD. Furthermore, research grants such as those done by Sumaira Foundation in 2022 to provide nonprofit organizations, researchers, and institutions funds for research into prevention and treatments for NMOSD. Hence, the above factors are likely to increase the growth of the during the forecast period.

Key Challenges

The high costs of NMOSD treatment are challenging the growth. Due to the lack of proper treatment, treatment only helps sustain symptoms to a degree. Drugs prescribed include corticosteroids, azathioprine, and new immunosuppressive treatments, including eculizumab, satralizumab, and inebilizumab. They are usually very expensive, with the annual cost of taking four 300 mg vials of eculizumab every two weeks being approximately USD 400,000. Hence, the high costs of adhering to treatment prescriptions are likely to hinder the growth of the during the forecast period.

Buy Now Full Report and Discover More

Market Customer Landscape

The report includes the adoption lifecycle of the, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Application Outlook (USD Million, 2017 - 2027)
    • Hospitals
    • Specialty clinics
    • Homecare
  • Type Outlook (USD Million, 2017 - 2027)
    • With aquaporin-4 antibodies
    • Without aquaporin-4 antibodies
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Australia
      • Argentina
      • Brazil

Neuromyelitis Optica Spectrum Disorder Market Scope

Report Coverage

Details

Page number

138

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.16%

Market growth 2023-2027

USD 173.48 million

Market structure

Concentrated

YoY growth 2022-2023(%)

6.1

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 37%

Key countries

US, Canada, UK, China, and India

Competitive landscape

 Leading industries, Market Positioning of industries, Competitive Strategies, and Industry Risks

Key companies profiled

AstraZeneca, Biogen Inc., Chugai Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., HBM Holdings Ltd., Horizon Therapeutics Plc, TG Therapeutics Inc., Mitsubishi Chemical Group Corp., and Opexa Therapeutics Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the neuromyelitis optica spectrum disorder market between 2023 and 2027
  • Precise estimation of the size of the neuromyelitis optica spectrum disorder market and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Vendor landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on vendor position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the industries competitive landscape and detailed information about industries
  • Comprehensive analysis of factors that will challenge the growth of neuromyelitis optica spectrum disorder market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global neuromyelitis optica spectrum disorder market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global neuromyelitis optica spectrum disorder market 2017 - 2021 ($ million)
    • 4.2 Application Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ million)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 Hospitals - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
    • 6.4 Speciality clinics - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Speciality clinics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Speciality clinics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Speciality clinics - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Speciality clinics - Year-over-year growth 2022-2027 (%)
    • 6.5 Homecare - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Homecare - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Homecare - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Homecare - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Homecare - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Application
      • Exhibit 46: Market opportunity by Application ($ million)
      • Exhibit 47: Data Table on Market opportunity by Application ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 48: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 50: Chart on Comparison by Type
      • Exhibit 51: Data Table on Comparison by Type
    • 7.3 With aquaporin-4 antibodies - Market size and forecast 2022-2027
      • Exhibit 52: Chart on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
    • 7.4 Without aquaporin-4 antibodies - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Type
      • Exhibit 60: Market opportunity by Type ($ million)
      • Exhibit 61: Data Table on Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 63: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 65: Chart on Geographic comparison
      • Exhibit 66: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 India - Market size and forecast 2022-2027
      • Exhibit 99: Chart on India - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on India - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on India - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on India - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 103: Market opportunity by geography ($ million)
      • Exhibit 104: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 105: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 107: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 108: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 109: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 110: Matrix on vendor position and classification
            • 12.3 AstraZeneca
              • Exhibit 111: AstraZeneca - Overview
              • Exhibit 112: AstraZeneca - Product / Service
              • Exhibit 113: AstraZeneca - Key news
              • Exhibit 114: AstraZeneca - Key offerings
            • 12.4 Biogen Inc.
              • Exhibit 115: Biogen Inc. - Overview
              • Exhibit 116: Biogen Inc. - Product / Service
              • Exhibit 117: Biogen Inc. - Key offerings
            • 12.5 Chugai Pharmaceutical Co. Ltd.
              • Exhibit 118: Chugai Pharmaceutical Co. Ltd. - Overview
              • Exhibit 119: Chugai Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 120: Chugai Pharmaceutical Co. Ltd. - Key offerings
            • 12.6 F. Hoffmann La Roche Ltd.
              • Exhibit 121: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 122: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 123: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 124: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 125: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.7 HBM Holdings Ltd.
              • Exhibit 126: HBM Holdings Ltd. - Overview
              • Exhibit 127: HBM Holdings Ltd. - Product / Service
              • Exhibit 128: HBM Holdings Ltd. - Key offerings
            • 12.8 Horizon Therapeutics Plc
              • Exhibit 129: Horizon Therapeutics Plc - Overview
              • Exhibit 130: Horizon Therapeutics Plc - Business segments
              • Exhibit 131: Horizon Therapeutics Plc - Key news
              • Exhibit 132: Horizon Therapeutics Plc - Key offerings
              • Exhibit 133: Horizon Therapeutics Plc - Segment focus
            • 12.9 Mitsubishi Chemical Group Corp.
              • Exhibit 134: Mitsubishi Chemical Group Corp. - Overview
              • Exhibit 135: Mitsubishi Chemical Group Corp. - Business segments
              • Exhibit 136: Mitsubishi Chemical Group Corp. - Key offerings
              • Exhibit 137: Mitsubishi Chemical Group Corp. - Segment focus
            • 12.10 Opexa Therapeutics Inc.
              • Exhibit 138: Opexa Therapeutics Inc. - Overview
              • Exhibit 139: Opexa Therapeutics Inc. - Product / Service
              • Exhibit 140: Opexa Therapeutics Inc. - Key offerings
            • 12.11 TG Therapeutics Inc.
              • Exhibit 141: TG Therapeutics Inc. - Overview
              • Exhibit 142: TG Therapeutics Inc. - Product / Service
              • Exhibit 143: TG Therapeutics Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 144: Inclusions checklist
                • Exhibit 145: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 146: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 147: Research methodology
                • Exhibit 148: Validation techniques employed for market sizing
                • Exhibit 149: Information sources
              • 13.5 List of abbreviations
                • Exhibit 150: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              neuromyelitis optica spectrum disorder market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis